JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

JNJ

229.2

+0.73%↑

UNH

368.8

+0.16%↑

TMO

477.53

+3.1%↑

ISRG

455.78

+1.06%↑

ABT

90.96

-1.17%↓

Начало・Списък с акции・Veracyte Inc

Veracyte Inc

Отворен

СекторЗдравеопазване

32.73 4.17

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

31.34

Максимум

33.01

Ключови измерители
By Trading Economics
Приходи	30M 49M
Продажби	8.8M 141M
P/E Средно за сектора	41.281 67.147
Марж на печалбата	34.967
Служители	755
EBITDA	22M 46M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+35.31% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-125M 2.7B
Предишно отваряне	28.56
Предишно затваряне	32.73

Настроения в новините

By Acuity

13%

87%

23 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

30.5 / 31.38 Подкрепа & съпротива

Veracyte Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2026 г., 23:53 ч. UTC

Печалби

Naver Posts Weaker First-Quarter Earnings

29.04.2026 г., 23:41 ч. UTC

Горещи акции

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29.04.2026 г., 23:55 ч. UTC

Печалби

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29.04.2026 г., 23:54 ч. UTC

Печалби

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29.04.2026 г., 23:52 ч. UTC

Печалби

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29.04.2026 г., 23:51 ч. UTC

Печалби

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29.04.2026 г., 23:24 ч. UTC

Печалби

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29.04.2026 г., 23:22 ч. UTC

Печалби

China Longyuan 1Q Net CNY1.70B, Down 14%

29.04.2026 г., 23:22 ч. UTC

Печалби

China Longyuan: Power Generation Down 2.9% as of End-March

29.04.2026 г., 23:20 ч. UTC

Печалби

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29.04.2026 г., 23:20 ч. UTC

Печалби

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29.04.2026 г., 23:19 ч. UTC

Печалби

China Vanke 1Q Loss Narrows>000002.SZ

29.04.2026 г., 23:18 ч. UTC

Печалби

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29.04.2026 г., 23:17 ч. UTC

Печалби

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29.04.2026 г., 23:15 ч. UTC

Печалби

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29.04.2026 г., 23:15 ч. UTC

Печалби

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29.04.2026 г., 23:13 ч. UTC

Печалби

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29.04.2026 г., 23:12 ч. UTC

Печалби

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29.04.2026 г., 23:11 ч. UTC

Печалби

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29.04.2026 г., 23:11 ч. UTC

Печалби

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29.04.2026 г., 23:04 ч. UTC

Печалби

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29.04.2026 г., 23:04 ч. UTC

Печалби

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Сравнение с други в отрасъла

Ценова промяна

Veracyte Inc Прогноза

Ценова цел

By TipRanks

35.31% нагоре

12-месечна прогноза

Среден 43 USD 35.31%

Висок 48 USD

Нисък 37 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Veracyte Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Veracyte Inc през последните 3 месеца.

Техническа оценка

By Trading Central

30.5 / 31.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Настроение

By Acuity

23 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.